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ABSTRACT
Background: The purpose of the presented work is to evaluate the last decade’s experience in surgical management
of central neurocytoma (CN) and elucidate on the treatment strategies and new options.
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Methods: The current series consists of the remaining 125 patients (70 females and 55 males) operated on
during the past decade from 2008 to 2018. Most tumors were resected through transcortical (n = 76, 61%), or
transcallosal (n = 40, 32%) approaches. In 5 (4%) patients with predominantly posterior location of the tumor,
non-dominant superior parietal lobule approach was utilized. Both approaches (transcortical + transcallosal)
were used in 4 (3%) of cases. Seven consecutive patients with large CN underwent prophylactic intraventricular
stenting to prevent hydrocephalus.
Results: Gross total resection was achieved in 45 patients (36%), subtotal resection (STR) in 40 (32%) cases.
After surgery, 63 (50%) patients had neurocognitive problems, including disorientation, attention deficit, global
amnesia, short-term memory deficits, and perceptual motor and social cognition problems. A total of 26 patients
(21%) had postoperative hemorrhage in the resection bed. Obstructive hydrocephalus was noted in 25 (20%)
patients. The entrapment of the occipital and/or temporal horns was observed in seven cases. None of the seven
patients with prophylactic intraventricular stents required shunting.
Conclusion: Although high rates of gross total or STR can be expected, the mortality and morbidity remain
significant even in the modern neurosurgical era. Prophylactic intraventricular stenting in patients with large
posteriorly located tumors with hydrocephalus may prevent ventricular entrapment and shunting. The main risk
factors for recurrence are presence of residual disease and Ki-67 index over 5%. Recurrent symptomatic tumors
should be treated surgically, whereas asymptomatic progression can be managed with stereotactic radiosurgery.
Both treatment modalities are associated with low risk of complications and high tumor control rates.
Keywords: Central neurocytoma, Postoperative complications and outcomes, Radiosurgery, Stereotactic
radiotherapy, Surgical resection

INTRODUCTION
Central neurocytoma (CN) was described as a distinct clinicopathologic entity by Hassoun
et al. in 1982.[18] CN account for <1% of all central nervous system (CNS) neoplasms.[33] It is
suggested that CN might be an embryonal tumor originating from the multipotent germinal

is is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others
to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
©2021 Published by Scientific Scholar on behalf of Surgical Neurology International

Surgical Neurology International • 2021 • 12(336)

|

1

Konovalov, et al.: Management of central neurocytomas

matrix cells located in the lateral ventricles.[2] CN is
biologically benign lesions composed of small uniform cells
with round nuclei and perinuclear halos. Mitotic figures
are rare.[17] This tumor may be associated with a relatively
favorable prognosis.[24-54] Patients with CN may present
with a wide variety of symptoms, primarily related to the
long-standing intracranial hypertension and obstructive
hydrocephalus. Maximally aggressive surgical excision
is a widely accepted mainstay of treatment. According to
the literature, it can be achieved in only 50–60% of the
patients.[24-41] Surgical challenges are the result of the deep
location, frequently large size at presentation, and high
vascularity.[41]
The largest clinical series included 438 patients by Rades and
Schild 92 cases by Qian et al., 84 by Konovalov et al., and
63 cases by Wang et al.[24,41,43,51] Early publications described
high rate of complications and low resection rates. In the
original series of Hassoun et al. and subsequent report by
Nishio et al., only 50% of the patients had gross total resection
(GTR).[19,38] In the last decade, however, a higher number
of patients underwent more radical resections, ranging
from 71% to 91% with acceptable morbidity.[8,23,41] In this
manuscript, the authors systematized the results of surgical
treatment of CN in the past decade from 2008 to 2018. The
main focus of this largest surgical series of patients with CN
to date is the analysis of anatomy and location of the tumor,
proper selection of surgical approaches, and evaluation of
outcomes.

MATERIALS AND METHODS
A total of 250 patients with CN were operated on at our
institution from 1992 to 2018. The current series consists
of the 125 patients (70 females and 55 males) operated on
during the past decade from 2008 to 2018. The patients’ age
ranged from 14 to 66 years (median 30 years). The study was
approved by the Research and Ethics Committee. The charts,
radiographic data, and surgical records were retrospectively
reviewed. The following data were extracted and analyzed:
age, sex, clinical presentation, radiographic characteristics
of the lesions, including size, location, and relationship with
surrounding anatomical structures, enhancement pattern,
intraoperative findings, extent of resection, perioperative
complications, and causes of mortality. All patients had their
first postoperative brain magnetic resonance imaging (MRI)
3 months after surgery, followed by annual MR studies,
unless clinically indicated otherwise.
The extent of tumor resection (ETR) was defined as (1)
GTR, when complete removal without any obvious residual
was achieved, (2) subtotal resection (STR), when small
residual nodular enhancement, or linear enhancement of the
resection bed, indistinguishable from the residual tumor was
present, and (3) partial resection (PR), when more than 10%
Surgical Neurology International • 2021 • 12(336)
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of the tumor was seen on postoperative MRI. The estimation
of the EOR was reported by the staff neuroradiologists based
on the postoperative MRI 3 months after surgery. All patients
underwent neuropsychological and psychiatric evaluation by
the staff psychologist and psychiatrist.
Statistical analysis
To establish the effect of clinical factors on overall survival,
a Kaplan–Meier analysis was performed. A log-rank test
(logarithmic rank test) and a Chi-square test were used
to assess differences between the two groups forming
the Kaplan–Meier curves in analysis 2 (e.g. complete or
incomplete resection) to identify the validity of differences
between the analyzed groups and obtain of risk ratio (RR).
A single-factor regression analysis, all significant factors for
which P < 0.05 was included in the multi-factor regression
analysis (Cox Proportional Hazards Model), was used to
assess the prognostic role of different factors. Assessment
of recurrence was performed by multifactorial regression
analysis with RR and 95% confidence interval. Differences
were considered valid at P < 0.05. Statistical analysis was
performed using the program “MedCalc” (version 19.6).
Clinical presentation
Symptoms associated with raised intracranial pressure (ICP)
were the most common clinical presenting findings in this series.
Seventy-eight patients (62%) had evidence of papilledema.
The extent of papilledema was graded according to the Frisen
grading system.[41] Fundoscopic evaluation was performed
preoperatively and postoperatively in each patient.[13]
Fifteen patients (12%) presented with hemiparesis. Memory
changes were noted in 40 patients (32%). Psychiatric and
cognitive problems were documented in 28 patients (22%).
Clinical findings are presented in more detail in [Tables 1 and 2].
Preoperatively, 76 patients had a Glasgow coma scale (GCS)
of 14–15, whereas 49 patients had GCS of 12–13.
Radiographic characteristics
All 125 patients underwent an MRI of the brain with
utilization of the standard brain tumor protocol with contrast.
In 83 patients (66%), the tumor was isointense to the brain
cortex on T1-weighted images. On T2 images, CN was seen as
heterogeneous lesions with multiple small hypointense cystlike areas, which were noted in 69% of the patients. About
60% of the neoplasms were larger than 4 cm in maximum
diameter. The largest mass had the longest linear dimension
of 8.0 cm. CN showed considerable anatomical variability in
their location within the ventricular system.
Based on the tumor size, we propose the following
classification: Group I: small tumors (<2 cm); Group II:
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medium size (2–4 cm); Group III: large (4–6 cm); and
Group IV: giant (>6 cm). According to the location, the
tumors can be classified into Group A: anterior (located in the
anterior horns); Group B: medial (located in the body of the
lateral ventricle); Group C: posterior (in the trigonum and the
occipital horn); and Group D: extensive (involving several
parts of the lateral ventricles or casting them) [Figure 1].
The numbers of patients in each group are summarized in
[Table 3]. In 30 patients, the tumor was extending into the
third ventricle. In Group A patients, tumor extension onto
the third ventricle was observed in 8 of 43 cases; in Group B
patients, in 12 of 54; and in 10 of 17 patients in Group D.

intraventricular mass suggestive of CN. Surgery was
contraindicated in patients with significant comorbidities, in
whom general anesthesia and potentially, prolonged surgery
was felt to be risky. In the absence of major comorbidities
and contraindications to general anesthesia, we recommend
maximally safe resection of even very large and giant tumors,
as surgery can be the patients’ only chance for survival. In
patients harboring tumors with very significant infiltrative
component, surgical indications are not straightforward. In
such instances, operative treatment may be considered on a
case by case basis with the main objectives to establish tissue
diagnosis, achieve maximally safe debulking and palliation.
Surgical treatment

Indications for surgery

Surgical approaches

Our approach was to recommend surgical resection in
all symptomatic patients with radiographic findings of

Most tumors in our series were resected through transcortical
(n = 76, 61%), or transcallosal (n = 40, 32%) approaches. In
five (4%) patients with predominantly posterior location of
the tumor, non-dominant superior parietal lobule approach
was utilized.

Table 1: Clinical presentation of 125 patients with CN.
Signs of increased ICP (chronic headaches,
nausea, and vomiting)
Memory decline
Psychiatric and cognitive problems
Hemiparesis and hyperreflexia
Visual field cuts
Double vision due to abducens nerve palsy
Seizures

78 (62%)

Anterior frontal transcortical approach is used in patients
with (1) CN located predominantly in the anterior horn
and the body of the lateral ventricle, (2) medial tumors with
lateral extension, and (3) large CN with lateral extension,
as well as tumors spreading to the contralateral side, but
only when ventriculomegaly was present. In patients with
very large tumors, casting most of the lumen of the lateral
ventricle, the craniotomy window had to be shifted more
anteriorly to achieve a favorable angle of attack along the
main axis of the neoplasm.

40 (32%)
28 (22%)
15 (12%)
2 (1.7%)
2 (1.7%)
8 (6%)

ICP: Intracranial pressure, CN: Central neurocytoma

Table 2: Papilledema in patients with CN according to the Frisen
grading system.

Transcallosal approach was preferred exposure in (1)
patients with medial or unilateral location of the tumor
without significant lateral extension and (2) small to
medium size medial tumors in both ventricles. The main
advantages of this approach were optimal visualization of
the tumor in both lateral ventricles and elimination of risks
associated with cortical transgression. Although the risks of
transcallosal approach include injury to the parasagittal veins
and subsequent venous infarct,[23,36] we did not encounter any

n

Papilledema
Normal Optic Disc
Minimal Degree of Edema
Low Degree of Edema
Moderate Degree of Edema
Marked Degree of Edema
Severe papilledema with atrophy and hemorrhages

47 (38%)
11(9%)
16 (12%)
21 (16%)
14 (11%)
30 (24%)

CN: Central neurocytoma

a

b

c

d

Figure 1: CN (a) limited to the frontal horn of the left lateral ventricle, (b) medial tumor, (c) posterior location, and (d) very large CN casting
the lateral ventricles. CN: Central neurocytoma.
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Table 3: Classification of CN based on the size and location.
Size
Group I:
small
(<2 cm)
Group II:
medium
(2–4 cm)
Group
III: large
(4–6 cm)
Group IV:
giant
(> 6 cm)
Total

Number of
patients

Location

Number of
patients

19 (15%)

Group A: anterior (in
the anterior horns)

43 (34%)

31 (25%)

Group B: medial (in
the body of the lateral
ventricle)
Group C: posterior
(in the trigonum and
occipital horn)
Group D: extensive
(involving several parts
of the lateral ventricles,
or casting them)
Total

54 (43%)

58 (46%)
17 (14%)

125

11 (9%)
17 (14%)

125

CN: Central neurocytoma

large bridging cortical veins in the surgical field in any of the
40 patients operated on through this approach. In 25 patients
with asymmetrical location of the tumor, we opened up the
corpus callosum most often between pericallosal arteries or
lateral to the ipsilateral pericallosal artery. The size of corpus
callosotomy depends on the size of the tumor, but never
larger than 2 cm in our series. Typically, the callosotomy
was carried out in the anterior or middle part of the body
of the corpus callosum, depending on the location of the
major bulk of the tumor. If severe hydrocephalus is present,
this approach allows the removal of tumors located more
posteriorly, in the body of the lateral ventricle and if the
lesion involved both lateral ventricles.
In four cases of giant tumors casting the lateral ventricles
and extending into the third ventricle, we used combined
approaches: three patients were operated on through
transcortical and transcallosal approaches, and in one case,
through bilateral transcortical approach.
Microsurgical nuances
We found that positioning of the patient on the operating
table with maximum utilization of gravity, adequate
brain relaxation and wide tumor exposure are critical to
successful removal of CN. In 35 patients, the surgeons
reported relatively soft consistency of the tumor, which
allowed an efficient utilization of regular suction and
ultrasonic aspirator. Multiple tumor vessels were
coagulated within the parenchyma of the tumor. We tried
to avoid or minimize the use of coagulation on the walls of
the lateral ventricles to minimize the risk of normal brain
damage. Securing the bleeding from the hypertrophied
ependymal vessels was frequently challenging. The
ependymal feeders commonly have very thin and frail
Surgical Neurology International • 2021 • 12(336)
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walls and continue to bleed, even as they retract into the
normal brain. Local hemostatic agents, such as gelfoam
soaking wet in thrombin and oxidized cellulose were
helpful. When the anterior-inferior aspect of the tumor
is mobilized, it is important to visualize the foramina of
Monro and carefully preserve the fornices. In 30 patients,
the tumors were extending into the third ventricle. In
these cases, we did not encounter any serious adhesions
between the tumor and the walls of the third ventricle.
The surgeons were able to mobilize and aspirate the
tumor through the foramen of Monro without the need to
widen the transforaminal exposure. Thalamostriate veins
were preserved in all patients, including 12 cases, when
the tumor was densely adherent to them, utilizing sharp
dissection. In eight cases, a very thin layer of tumor was
left on the thalamostriate veins to preserve them. Septal
veins were either unidentifiable, or sacrificed in all cases, as
neoplasms invaded septum pellucidum. When the tumor
invaded choroid plexi, we tried to preserve their largest
draining veins until the very end of resection. Their early
sacrifice could contribute to significant intraoperative
hemorrhage that resulted in challenging hemostasis during
removal of the posterior pole of the tumor. We attempted
maximally aggressive resection, as bleeding into the
residual mass can result in potentially life-threatening
sequela of postoperative intraventricular hemorrhage and
even casting of the ventricular system with blood, resulting
in obstructive hydrocephalus. To prevent obstructive
hydrocephalus, microsurgical fenestration of the septum
pellucidum was performed in almost all cases [Figure 2].
Ventriculostomy catheter was left in 85 (68%) of the patients.
Seven most recent consecutive patients with large CN
underwent prophylactic intraventricular stenting to prevent
hydrocephalus between the anterior and posterior horns
of the lateral ventricles or between the lateral and third
ventricles. Early postoperative brain computed tomography
(CT) (within 3 h of surgery) was performed in all cases to
rule out acute postoperative changes, such as hemorrhage
and hydrocephalus.
Neuromonitoring of somatosensory evoked potentials
(SSEP) and motor evoked potentials (MEP) was utilized
in 82 patients with posteriorly located, extensive tumors,
and tumors infiltrating the walls of the lateral ventricles. In
addition, continuous subcortical stimulation was performed
during tumor resection. The authors did not monitor patients
with smaller and anteriorly located neoplasms.

RESULTS
Extent of resection
In this series of 125 patients, GTR was documented in
45 (36%), STR in 40 (32%), and PR in 40 (32%) of patients.

Konovalov, et al.: Management of central neurocytomas

Table 4: Size of the tumor and extent of resection.
Group/Size
of the tumor

a

GTR

STR

GTR+STR

PR

Total

Group I:
16
3
19 (100%)
small (<2 cm)
Group II:
15
7
22 (69%) 9 (31%)
medium
(2–4 cm)
Group III:
12
23
35 (66%) 23 (34%)
large (4–6 cm)
Group IV:
2
7
9 (50%) 8 (50%)
giant (>6 cm)
Total
45 (36%) 40 (32%) 85 (68%) 40 (32%)

b

19
31
58
17
125

GTR: Gross total resection, STR: Subtotal resection, PR: Partial resection
c

d

Figure 2: Basic principles of microsurgical resection: (a) in most
cases, the tumor is relatively soft, which allows an efficient use of
the regular suction and ultrasonic aspiration; (b) multiple tumor
vessels are coagulated in the parenchyma of the tumor. The use of
coagulation on the walls of the side ventricles should be avoided
or minimized; (c) if the tumor is located in the lower part of the
anterior horn, it is important to visualize and release the foramen
of Monro by removing the tumor through it without the need to
expand the transforaminal exposure while preserving the fornix.
Thalamostriate vein and the vein of the choroid plexus should be
preserved; (d) septum pellucidotomy is performed to interconnect
the ventricles.

Further analysis of the relationship of the preoperative
tumor volume and the EOR demonstrated that GTR/STR
was achieved in 100% of patients with tumors <2.0 cm
in largest diameter, in 69% of the patients with tumors
measuring 2–4 cm, in 66% with tumors measuring 4–6 cm,
and in only 50% when lesions were larger than 6 cm
[Table 4].
In patients with anterior tumors (Group A), aggressive
resection (GTR and STR) was achieved in 65% of cases (28
out of 43 patients). In patients with medial tumors (Group B),
aggressive resection (GTR and STR) was achieved in 74% (40
out of 54) of patients. In Group C patients (posterior tumors),
64% (7 from 11) had aggressive resection. In patients with
extensive tumors (Group D) GTR/STR was possible in only
56% of cases (9 out of 16 patients) [Table 5].
Even with neuromonitoring, 22 of 82 patients with large
posterior infiltrating lesions developed either worsening of
the weakness, or new motor deficits. Interestingly, only 15
of 22 patients had documented decrease in the amplitudes
of SSEP and MEP. Further resection of the periventricular
and/or thalamic parts of the tumor was stopped in each case
when alarming electrophysiological changes occurred, if
hemostasis was adequate.

Postoperative complications
Hemorrhagic complications
A total of 26 patients (21%) were found to have postoperative
hemorrhage in the resection bed. In all cases, the bleeding
was associated with residual tumor. Postoperative hematomas
were more common in patients with large or giant tumors
(n = 22). Radiographically, the volume of hemorrhage
was comparable with, or larger than the volume of the
original tumor in all cases. We found that 85% of the bleeds
(n = 22) occurred within the first 24 h after surgery. Only
three patients were stable enough to manage conservatively,
whereas in 19 cases, surgical revision and evacuation of the
intraventricular hematoma with resection of residual tumor
were performed within 24–48 h postoperatively. In addition,
four patients experienced second rebleeding on postoperative
days 3–5 (after the first revision). These patients were
operated on again within 4–6 days after craniotomy for tumor
removal. In the group of 19 patients who had to undergo an
emergent evacuation of the hematoma due to significant
mass effect, brain shift and/or herniation, two patients died
and two were discharged in persistent vegetative state.
Further analysis of hemorrhagic complications and their
relationship with the type of approach and location of the
tumor showed that hematomas most commonly occurred
after transcortical approach (16 of 76 patients/64%),
followed by combined approach (2 of 4 patients/50%),
and less commonly, after transcallosal approach (8 of
40 patients/31%). Postoperative hematomas were most
common in group C (3 of 11 patients/27%), followed
by Group A (9 of 43 patients/21%); Group D (3 of
17 patients/18%); and Group B (8 of 54 patients/15%).
Subdural collections
Three patients developed acute postoperative subdural
hematomas and one patient was diagnosed with subdural
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Table 5: Location of the tumor, surgical approach, and extent of resection.
Surgical approach

Anterior transcallosal
Anterior transcortical
Posterior transcortical
Combined
Total

Group A: anterior
tumors (n=43)

Group B: medial
(n=54)

Group C: posterior
(n=11)

Group D: extensive
(n=17)

Tot (GTR/STR)

PR

Tot (GTR/STR)

PR

Tot (GTR/STR)

PR

Tot (GTR/STR)

PR

8 (5/3)
20 (12/8)
28 (17/11)

4
11
15

20 (11/9)
20 (11/9)
40 (22/18)

8
6
14

6 (3/3)
1 (1/0)
7 (4/3)

3
1
4

6 (1/5)
1(0/1)
3 (1/2)
10 (2/8)

4
2
1
7

Total

40
76
5
4
125

GTR: Gross total resection, STR: Subtotal resection, PR: Partial resection

hygroma 8 days after craniotomy. None of them required
surgical evacuation.
Impaired CSF circulation and absorption
Hydrocephalus
Obstructive hydrocephalus was noted in 25 (20%)
patients. In 80% of the cases progressive worsening of
ventriculomegaly occurred acutely, on postoperative
days 2 and 3. In 19 cases, the external drain was placed.
Consequently, 14 of the 19 patients with external drain
ended up with ventriculoperitoneal shunt. Shunting
procedures for obstructive hydrocephaly were performed
in a delayed fashion (10–35 days after the first surgery),
once CSF had become visually clear. In 5 of 14 patients who
underwent shunt placement, the procedure was performed
on postoperative days 30–35 due to meningitis, which was
treated with IV vancomycin until CSF analysis became
normal and cultures negative. We did not observe any
mortality or significant morbidity related to CSF infection.
Interestingly, although we did not establish any clear
correlation between the extent of resection and development
of hydrocephalus, over 50% of hydrocephalus cases occurred
after STR and PR of the tumor. In 15 patients after GTR, the
occlusion was at the level of the foramina of Monro due to
direct obstruction by the blood clots. In 10 patients after
PR, the obstruction was related to the presence of both,
“strategically placed” residual tumor tissue in the vicinity
of the foramina of Monro and blood clots. Hydrocephalus
developed in 17 patients after transcortical approach, five
patients after transcallosal approach, two patients after
combined approach, and in one case after tumor resection
through the superior parietal lobule.
Entrapment of the occipital and/or temporal horns
A unique complication was encountered in Group C patients
(with posteriorly located tumors): the entrapment of the
occipital and/or temporal horns. This problem occurred in a
total of 7 of 11 patients in Group C. Once the high risk of
Surgical Neurology International • 2021 • 12(336)
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entrapment was realized, all seven subsequent patients were
prophylactically stented to establish connection between the
posterior-inferior aspects of the lateral ventricles and the rest
of the ventricular system.
In three of seven patients, the intraventricular stents extended
through the foramina of Monro and the aqueduct [Figure 3].
Intraventricular stenting was performed with utilization of
the ventricular catheter, trimmed to achieve desired length.
In all cases, surgeons added several side holes to minimize
the chances of occlusion. The stents were not anchored.
There were no incidents of stent occlusion, malfunction, or
migration. None of the patients after stenting required shunt
placement or any other type of revision surgery.
Neurological outcome
All postoperative patients experienced early neurological
and cognitive worsening to some extent. In half of the
patients (n = 62, 50%), the symptoms were mild, included
increased somnolence, decreased level of activity,
sensorimotor agitation, and anxiety, and improved within
the 1st postoperative week. The other 63 patients had a
more complicated course, characterized by significant
disorientation, attention deficit, global amnesia, shortterm memory deficits, and perceptual motor and social
cognition problems. In 22 (of 63 patients in this group),
the neurocognitive problems remained permanently. All
28 patients (22%), who presented with neurocognitive deficits
before surgery, were found to have further neurocognitive
decline [Table 6]. Postoperative GCS score distribution
among the alive patients was 14–15 in 51 cases, 12–13 in 62,
and 9–11 in seven patients.
Analysis of the postoperative complications and tumor
location revealed the following relationships: patients with
anteriorly located lesions (type A and/or B) were more
likely to have memory and cognitive disturbances, whereas
patients with posteriorly located and extensive tumors (type
С and/or D) were prone to have signs of pyramidal tract
damage (i.e. hemipares) and speech disturbance. Among the
11 patients with posteriorly located tumors (types C), partial
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Table 6: Clinical presentation of 125 patients with CN before and
after microsurgery.
Clinical manifestation

a

b

Figure 3: (a) Preoperative MRI (T1 with contrast) showing the
tumor involving both lateral ventricles; (b) postoperative brain
CT after resection of recurrent neurocytoma and stenting of the
left lateral ventricle: the longer stent extends from the occipital
horn of the right lateral ventricle to the frontal horn on the left; the
shorter stent connects the right frontal horn and the body of the
lateral ventricle. MRI: Magnetic resonance imaging, CT: Computed
tomography.

hemianopsia was diagnosed in two. After surgery, these
patients and two others developed complete hemianopsia on
formal visual field evaluation [Table 7].
Mortality
Five patients (4%) died in the early postoperative period. All
deaths were related to hemorrhage into the residual tumor,
with resultant mass effect and compression of the brainstem.
Two patients underwent revision within 24 h of surgery.
Although some improvement of the brainstem function was
noted after decompression (i.e. hemodynamic stabilization),
their neurological status remained extremely poor. In one
patient, postoperative hemorrhage was complicated by sepsis
and subsequent multisystem organ failure that ultimately
lead to expiration.
Tumor recurrence
CN’s are slowly growing tumors. Therefore, only patients
with long-term follow up were selected for analysis of data
on recurrence. After surgical treatment from 2008 to 2018,
84 patients with CNs were followed for 2–10 years (mean
6 years). Of those 84 patients, 26 (30.2%) were found to
have tumor recurrence within 12–96 months after surgery;
in 19 cases after incomplete resection, and in seven cases
after GTR. Two-year progression-free survival (PFS) was
documented in 94% and 5-year PFS in 73% of the patients
[Figure 4].
The multivariate analysis of factors potentially affecting the
recurrence rate revealed that the EOR and the range of Ki-67
proliferative index were associated with the most significant
impact [Figure 5 and Table 8]. Five-year PFS was 90% after

Before surgery After surgery

Memory decline
Other psychiatric and cognitive
disturbances
Signs of increased ICP
Upper motor neuron signs
(hemiparesis and hyperreflexia)
Double vision due to abducens
nerve palsy
Visual field loss
Speech disorders
Overall number of patients

40 (32%)
28 (22%)

62 (50%)
32 (27%)

78 (62%)
15 (12%)

22 (18%)

2 (1.7%)

4 (3.6%)

2 (1.7%)
125

4 (3.6%)
11 (9%)
120 alive
patients

ICP: Intracranial pressure, CN: Central neurocytoma

Table 7: Comparison of the nature of postoperative complications
with tumor localization and lateralization.
Clinical
presentation
Memory decline
Other psychiatric
and cognitive
disturbances
Upper motor
neuron signs
(hemiparesis and
hyperreflexia)
Double vision
due to abducens
nerve palsy
Visual field loss
Speech disorders

Group A: Group B: Group C: Group D:
anterior
medial posterior extensive
(n=43)
(n=54)
(n=11)
(n=17)
23
6

27
14

2
1

10
11

0

7

7

8

0

0

0

4

0
0

0
2

2
4

2
4

GTR and only 65% after subtotal and partial resection
(P < 0.05). In patients with Ki-67 index <5%, 83% experienced
5-year PFS versus only 40% in patients with Ki-67 index ≥5%
(P < 0.05). The Kaplan–Meier estimator curve illustrating the
PFS in relation to Ki-67 index is provided in [Figure 6].
Management of recurrent tumors
Continuous observation
Of 26 patients with recurrent CN’s, eight cases were
managed conservatively with serial imaging studies because
the documented increase in size of the recurrence was
≤2 mm in each case and Ki-67 index ≤5%. None of the
patients in this subgroup showed any further increase in the
tumor size.
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Table 8: The multivariate analysis of factors potentially affecting the recurrence rate: the EOR and the range of Ki-67 proliferative index
were associated with the most significant impact.
b

SE

Wald

P

Exp (b)

95% CI of Exp (b)

2.3250
0.8698
1.2911

0.4337
0.4062
0.4115

28.7427
4.5850
9.8430

<0.0001
0.0323
0.0017

10.2265
2.3864
3.6369

4.3710–23.9262
1.0764–5.2909
1.6234–8.1476

Covariate
Ki_67
Max_diameter
EOR

EOR: Extent of resection, SE: Standard error, CI: Confidence interval

Figure 6: Progression-free survival and Ki-67 values (P<0.05).

Figure 4: Progression-free survival.

neurologically and cognitively or remained unchanged.
None of the patients experienced surgical complications.
The authors impression was that repeat surgeries were less
technically challenging, as the lesions were smaller than in
the first surgery and tended to be less vascular. In all cases,
the lesions were well defined with clearer borders than in
the original procedures. The images of one of the illustrative
cases are depicted in [Figure 7].
Radiation therapy
Eleven patients were found to have significant interval
enlargement of the tumor on follow-up MRI. They did not
have evidence of increased ICP/mass effect, or impaired
CSF circulation/hydrocephalus. These patients were felt to
be good candidates for radiation therapy (XRT). The choice
of XRT methods depended on the volume of residual tumor
and the extent of tumor spread in the ventricular system. The
XRT techniques are summarized in [Table 9].

Figure 5: Survival function at mean of covariates.

Repeat surgical resection
Seven patients were diagnosed with significant postoperative
radiographic tumor progression associated with masseffect, hydrocephalus, and/or development of neurological
deficits. They subsequently underwent repeat craniotomy
for resection of recurrence. In five of these cases, GTR
was achieved, 82% of patients in this subgroup improved
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All 11 patients with recurrent CN treated with XRT
demonstrated satisfactory results over the mean follow-up
of 2.5 years. The tumor decreased in size in 4 patients and
remained stable in 7 [Figure 8].
None of the patients had evidence of radiation-induced
damage to the surrounding tissues on follow-up MRI. Eight

Konovalov, et al.: Management of central neurocytomas

Table 9: XRT techniques, dosage and fractionation used in patients with recurrent CN.
Type of XRT

Tumor
Volume, cm3

Mean
Volume, cm3

Total radiation
dose, Gy

Marginal
dose, Gy

Fractionation XRT machine

Number of patients

SRS radiosurgery

0.5–4.5

0.3

-

10–16

Hypofractionated
XRT
Standard
fractionated XRT

2.7–11.7

8.8

21.0–27.5

-

2
1
3

12.0–62.0

35.0

54

-

Single fraction Cyber Knife®
Gamma Knife®
7 Gy × 3;
Cyber Knife®
5.5 Gy × 5
1.8 Gy × 30; Novalis®
2 Gy × 27
TrueBeam®

3
2

XRT: Radiation therapy, CN: Central neurocytoma, SRS: Stereotactic radiosurgery

b

a

c

d

Figure 7: (a) Preoperative MRI of the tumor with Ki-67 index >5% (T1 with contrast); (b) T1 MRI with contrast 6 months after surgery, with
evidence of GTR of the tumor; (c) T1 MRI with contrast 3 years after surgery showing large recurrent tumor; (d) immediate postoperative T1
MRI with contrast demonstrated GTR of the lesion. MRI: Magnetic resonance imaging, GTR: Gross total resection.

studies between 6 and 18 months after XRT. These patients
were managed with either endoscopic or open microsurgical
membrane fenestration or lysis of intraventricular adhesions
with successful restoration of normal CSF circulation
in all cases [Figure 9]. We did not observe any cases of
pseudoprogression.

DISCUSSION
a

b

Figure 8: Illustrative case of the XRT plan in a patient after standard
fractionated treatment to the recurrent tumor (a), total dose of
57.6 Gy; T1 MRI 12 months after XRT demonstrated significant
decrease in size of the tumor (b) XRT: radiation therapy, MRI:
magnetic resonance imaging.

patients treated with XRT developed clinically significant
problems with CSF circulation and/or absorption. In two
cases of communicating hydrocephalus shunt placement
was performed 6 and 12 months after XRT respectfully.
The remaining six patients developed entrapment of the
temporal and/or occipital horns of the lateral ventricles. This
complication was observed when the tumor extended into
the posterior body and/or trigonum of the lateral ventricles.
The ventricular entrapment was discovered on neuroimaging

CN is biologically benign, slowly growing neoplasms with
an overall favorable chance of survival. CN is most common
in young adults, potentially most productive age group
(between ages of 20 and 40 years).[20,36,54]
Our literature search identified close to 500 reported cases
of CN. The largest clinical series to date was by Rades and
Schild with 438 cases (365 adults and 73 pediatric patients).
Interestingly, 87 patients in this series were found to have
atypical CN.[43] Other large series included 92 patients by
Qian et al., 84 and 115 patients by Konovalov et al., and
63 cases by Wang et al.[24,25,41,51]
These series are summarized in [Table 10].
Early reports including our recent publication described
high rates of complications and low resection rates.[24] In the
original series of Hassoun et al. and subsequent report by
Nishio et al. only 50% of the patients had GTR.[19,38] In the
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Table 10: The most representative series of patients with neurocytomas and the results of surgical treatment.
Author

Year

n

Radical resection

Hydrocephalus

Shunt

Postoperative neurologic
symptomatology

Mortality

Qian et al., 2012 [41]
Konovalov et al., 2006[24]

2012
2006

92
84

62%
33 (40%)

14%
14 (17%)

40%
17 (21%)

3 (2.5%)
10 (12%)

Wang et al., 2018[51]
Chen et al., 2016[8]
Kim et al., 2013[23]
Hallock et al., 2011[17]
Present series

2018
2016
2013
2011
2020

63
32
58
19
125

65 (71%)
11+48 (13+58%)
(GTR+STR)
34 (54%)
29 (91%)
42 (88%)
10 (53%)
45+40 (68%)
(GTR+STR)

25 (40%)
3 (9%)
10 (17%)
25 (20%)

1 (3%)
14 (11%)

14 (22%)
6 (19%)
14 (24%)
16%
22 (18%)

5 (8%)
0
1 (2%)
5%
5 (4%)

GTR: Gross total resection, STR: Subtotal resection

tissue for diagnosis, decompress the brain and treat
hydrocephalus.[34,47]
Challenges related to the tumor location and size

a

CN is characterized by their deep intraventricular location
and ample blood supply from the choroidal arteries. Other
factors include their large size at presentation and early
involvement of such critical structures as thalami and
fornices.[8,19,23,26,29,34,36,38,51] The current consensus is that
aggressive resection is not recommended if the tumor
infiltrates the fornices, thalami, or encases the large
intraventricular veins.

b

Many authors noted strong correlation between the EOR and
tumor recurrence.[1,39,42,50] However, due to the mechanism
of the tumor growth with wide infiltration of the ventricular
walls, GTR might be challenging in many cases, and safely
possible only in smaller and better circumscribed lesions.
c

d

Figure 9: (a) CN involving both lateral ventricles before and
(b) after surgery; (c) entrapment of the occipital horn of the left
lateral ventricle (6 months after surgery); (d) follow-up MRI 6
months after open microsurgical lysis of intraventricular adhesions,
showing successful interval decompression of the trapped ventricle.
CN: central neurocytoma, MRI: magnetic resonance imaging.

last decade, however, a higher number of patients underwent
more radical resections, ranging from 71% to 91% with
acceptable morbidity.[8,23,41]
This was probably due to earlier detection of tumors by
neuroimaging, improvements in microsurgical techniques
and introduction of routine image-guidance and
intraoperative MRI.[2] Nowadays, maximal safe resection
has become the standard first line of treatment in patients
with CN. The main objectives of surgery are to provide
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Our GTR rate is lower than in the largest published series
up to date by Chen et al.[8] It is felt to be mainly due to
larger size of the lesions at presentation in our report. In the
present study, 69 of 125 patients (55%) presented with large
or giant tumors. The mean tumor size was 5.2 cm, compared
to 4.8 cm reported by Chen et al. We demonstrated a very
strong relationship between the size and the extent of
resection of the tumor. GTR/STR was achieved in 100% of
patients with tumors <2.0 cm in largest diameter, in 69%
of tumors measuring 2–4 cm, in 66% of tumors measuring
4–6 cm, and in only 50% when lesions were larger than
6 cm. In five cases, we utilized endoscopic assistance,
primarily to visualize residual tumor in the ventricular
system. Despite successful use of the 0° and 30° scopes and
adequate magnification, in three cases the surgeons failed
to differentiate tumor from normal tissue. Overall, our
experience with endoscopic assistance was not felt to be
clearly advantageous.

Konovalov, et al.: Management of central neurocytomas

Although aggressive resection should be an ideal goal,
Leenstra et al. reported no difference in overall outcome in
patients after GTR and STR.[26] Other authors recommend
a more conservative resection combined with stereotactic
radiosurgery (SRS) as a method of choice to minimize the
treatment related risks. The combined approach provides
excellent long-term control of this biologically low-grade
neoplasm.[20]
Choice of the approach
The choice of the surgical approach depends on three
factors: (1) location of the tumor, (2) size, and (3) extent of
hydrocephalus.[20,31,41] Transcortical approach through the
premotor cortex was used in the majority of our patients.
This approach is advantageous in cases associated with
significant ventriculomegaly and asymmetrically located
tumors occupying large portions of the lateral ventricles.
Transcallosal approach is preferable in centrally located
tumors in the anterior parts of the lateral ventricles. In rare
cases of giant CN, a combined approach might be necessary.
Various combinations of transcallosal and transcortical and
bilateral transcortical approaches can be utilized. Thorough
analysis of preoperative imaging studies can be very helpful
in selecting the best approach. Kim et al. found no difference
in the extent of resection and the actuarial overall survival
between the surgical approaches.[23] However, there was a
difference in functional outcomes, especially in the risk of
cognitive deficits and seizures, that were more common after
transcortical resection. Therefore, if feasible, interhemispheric
transcallosal route should be the approach of choice, as it
provides the least disruptive anatomical corridor associated
with smaller risk of approach related complications.[8]
The ipsilateral interhemispheric posterior parieto-occipital
approach and the posterior interhemispheric transfalcine
transprecuneus approach can be utilized to resect tumors
located in the trigonum and the occipital horn of the lateral
ventricle. These approaches provide a wider surgical corridor,
which leads to minimal retraction, sparing of the optic
radiation, temporal, and parietal cortices and early access to the
arterial feeders. The disadvantages include significant ipsilateral
hemispheric retraction; long working distance; and risk of
injury to contralateral hemisphere.[5,11,30] To prevent damage to
the critical visual fibers in patients with very posteriorly located
CN, the ipsilateral interhemispheric posterior parieto-occipital
and the posterior interhemispheric transfalcine transprecuneus
approaches can be considered a reasonable alternative to the
trans-superior parietal lobule approach.[40]
Prevention and management of complications
Most CN series report high incidence of complications,
including
hemorrhage,
obstructive
hydrocephalus,

neurological deficits, seizures, and cognitive deficits.[8,19,2224,38,45,51]
Lubrano et al. reported 66% complication rates in
their multicenter study. The main causes of postoperative
disability were motor deficits and/or aphasia, memory
problems (29%), and hydrocephalus (26%).[29] Higher
complication rates in early publications might be related
to larger size of the tumor, likely due to delayed patient
diagnosis in the previous decade.[15,19,36,38,45] In our series, most
significant complications were associated with hemorrhage
and/or hydrocephalus. Postoperative hemorrhage is probably
the most life-threatening complication. We agree with the
observation of Chen et al. that difficult hemostasis and
frequent hemorrhagic complications in CN can be explained
on the basis of abundant blood supply with presence
of multiple pathologic vessels without smooth muscle
cells and well-developed network of cavernous venous
structures.[8] Hematomas typically form in the residual
tumor and frequently require revision of craniotomy and
evacuation. Eighteen of the 26 patients with life-threatening
hematomas in our report were operated on emergently. The
morbidity and mortality in this group of patients were very
high: two of them died and two were discharged in persistent
vegetative state. We also noted that none of the patients
operated on in a delayed fashion, that is, 4–6 days after the
hemorrhage, or after the first emergent revision, died. In
fact, all of them improved after hematoma evacuation. These
findings support our previous observation that delayed
evacuation of hematoma (i.e. after stabilization of the clot)
may be beneficial in selected stable patients and can lead to
somewhat easier hemostasis.[24] Analysis of the hemorrhagic
complications revealed that postoperative hematomas occur
twice as frequent after transcortical approach, compared to
transcallosal. This finding might be related to the fact that
transcortical approach is typically selected for larger tumors
that also tend to be more infiltrative with more robust blood
supply from the surrounding periventricular white matter.
We did not find any correlation between the occurrence of
hematoma in the resection bed and location of the tumor.
Chaves et al. reported resection of a giant pediatric CN after
successful preoperative embolization, which supposedly
resulted in smaller blood loss.[7] The patients in our series did
not receive preoperative embolization.
Obstructive hydrocephalus is another dangerous
complication, especially if develops acutely in the early
postoperative period. Soliman suggested that tumor
remnants and blood clots are the main causes of obstruction
of the CSF pathways.[47] We concur with this observation.
The incidence of early postoperative hydrocephalus in
the current study (20%) is almost half the incidence in
the historic series and comparable to the results reported in
the modern studies.[8,19,38,51] Seven patients in this series were
found to have entrapment of the occipital and/or temporal
horns. All these patients belonged to Group C, harboring
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posteriorly located tumors. Prophylactic intraventricular
stenting appears to be beneficial in eliminating the risk
of entrapment and subsequent shunting. The authors
consider stenting a more physiological and less invasive
procedure, as the CSF flows across the stent in both
directions, as opposed to unidirectional flow toward the
shunt, and then outside of the cranium. This is probably a
pathophysiological basis for essential absence of cases of
stent occlusion in this series. However, if CSF resorbtion is
impaired, stenting alone may be insufficient. The authors
acknowledge the small number of patients who underwent
stenting and recommend a judicious use of this technique
in selected cases of large posteriorly located tumors with
intraventricular obstruction.
Postoperative hydrocephalus was twice as common after
transcortical resection (22.3%) as after transcallosal resection
(12.5%). The difference is likely also related to the larger
volume and extent of ventricular involvement in patients
undergoing transcortical resection. In addition, transcallosal
approach allows better visualization and decompression of
both foramina of Monro and the third ventricle.
Long-term management
Between 2008 and 2016, the authors utilized the 2008 World
Health Organization (WHO) classification. After 2016, the
new WHO classification has been used.[27,28] Ki-67 index
was established in all patients to determine proliferative
activity. Ki-67 index has become a very useful parameter
in prognostication and evaluation of tumor response to
treatment.[10,25,48] In our series of 25 patients with disease
progression, 14 (56%) had Ki-67 index ≥5%. This factor was
found to be statistically significant on multivariate analysis
(P < 0.05). Conversely, low Ki-67 index (<5%) combined

with aggressive tumor resection was found to be associated
with longer PFS.
Patients with recurrent CN could be considered candidates
for repeat microsurgical resection or XRT. Seven of
16 patients in this series, with radiographic and symptomatic
progression underwent repeat microsurgical resection. Most
of them (86%) had a GTR of the tumor with good results,
which proves that repeat surgical resection remains safe and
effective long-term management strategy.
XRT was reserved for the patients with radiographic
progression without evidence of increased ICP and/or
hydrocephalus. The high efficacy of various forms of XRT was
demonstrated in several publications with adequate long-term
tumor control rate exceeding 80%.[9,48] The largest series of CN
treated with XRT up to date, is a report of 42 consecutive cases
treated with SRS, by Karlsson et al. in 2012.[21] The majority
of their patients underwent SRS to the tumor remnants after
STR. About 91% and 81% tumor control rates were achieved
at 5 and 10 years, respectively.[3,4,12,14] The results of SRS in
patients with CN’s are summarized in [Table 11].
Our data and review of the literature demonstrate that
the use of various XRT modalities in recurrent CN cases
is safe and associated with high tumor control rates. Rare
cases of hemorrhage, edema, and radiation necrosis are
typically self-limited and not associated with major negative
clinical sequela. In patients with obstructive hydrocephalus,
who would otherwise be considered good candidates
for XRT, surgical CSF diversion (using microsurgical
approaches, shunting, and/or stenting) should be performed
before irradiation. Although we did not observe tumor
pseudoprogression in our series, this condition was described
in the literature. Pseudoprogression is associated with benign
course and managed conservatively.

Table 11: The results of SRS in patients with CN’s in the literature.
Author

n

Type of equipment

Yamanaka et al., 2016 [52]

36

Monaco et al., 2015[34]
Kim et al., 2013[22]
Karlsson et al.,2012[21]
Genc et al., 2011[14]
Yen et al., 2007[53]
Martin et al., 2003[32]
Anderson et al., 2001[3]
Bertalanffy et al., 2001[4]
Cobery et al., 2001[12]

V (ml)

Max dose (Gy)

Follow-up
(months)

Tumor control
rate (%)

Gamma Knife®

4.9

15.0

54.5

94

8
20
42
22
7

Gamma Knife®
Gamma Knife®
Gamma Knife®
Gamma Knife®
Gamma Knife®

5.5
11.0
12.0
13.4
6.0

14.6
15.4
13.0
16.4
16.0

63.3
103
73
36
60

100
85
95
95
100

4
4
3
4

Novalis®
Gamma Knife®
Gamma Knife®
Gamma Knife®

3.2
7.0
3.9
14.8

16.5
17.0
12.8
10.5

33
17
60
44

100
100
100
100

SRS: Stereotactic radiosurgery, CN: Central neurocytoma

Surgical Neurology International • 2021 • 12(336)

|

12

Complications
Hemorrhage-2;
Radiation necrosis-1
None
Edema-1
None
Hemorrhagе-1
Alopecia-1,
Edema-1, Radiation
necrosis-1
None
None
None
None
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Rarely, CN can spread along the CSF pathways. Goyal et al.
described a case of periventricular atypical neurocytoma
after STR. The patient in this report underwent adjuvant
focal radiotherapy and subsequently developed local and
spinal leptomeningeal recurrence treated with salvage
chemotherapy. The disease continued to progress, and the
patient was offered comfort measures.[16] Fortunately, we did
not observe this phenomenon in our series.
A literature review of 19 atypical cases with malignant
behavior showed MIB-1 LI above 2% in 12 of 14 cases, and
above 10% in those progressing within a year.[35] Seventeen
patients had craniospinal dissemination. However,
craniospinal irradiation was given to only three patients after
documented craniospinal dissemination.[6,37,49] Rades and
Schild, after an extensive review of 438 patients, including
87 atypical CNs, with a minimum follow-up of 1 year, gave
treatment recommendations for various CN subgroups. No
adjuvant therapy is required after GTR. After STR, adjuvant
radiation improves survival in atypical lesions in adults
but not in children, while local control improves across all
subgroups. Adults need doses exceeding 54 Gy while doses
above or below 50 Gy have comparable outcomes in children.
Authors recommended adjuvant RT doses of 50 Gy in
children, 50–54 Gy in typical CN, and 56–60 Gy in atypical
CN.[43]
In addition to leptomeningeal dissemination, other unusual
cases of CN spreading all the way down into the fourth
ventricle[44] and association of CN with other neoplasms,
such as pituitary adenoma[46] have been described, none of
which occurred in our patients.

CONCLUSION
CN remains surgically challenging lesion. The results of this
series are comparable to the results reported in previous
studies. Although high rates of GTR or STR can be expected,
the mortality and morbidity remain significant even in the
modern neurosurgical era, regardless of the approach. Large
size of the tumor, presence of hydrocephalus and preoperative
neurological or cognitive deficits are associated with lesser
extent of resection and poorer outcome. Prophylactic
intraventricular stenting in patients with large posteriorly
located tumors with hydrocephalus may prevent ventricular
entrapment and shunting. Early diagnosis and continuous
refinement of microsurgical techniques along with judicious
use of multimodality treatment may positively impact the
outcomes.
Despite an overall favorable prognosis, up to a third of the
patients experience disease progression and recurrence. The
main risk factors for recurrence are presence of residual
disease and Ki-67 index over 5%. Recurrent symptomatic
tumors should be treated surgically, whereas asymptomatic
progression can be managed with SRS. Both treatment
modalities are associated with low risk of complications and
high tumor control rates.
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Nil.

Our study has several limitations: (1) the retrospective
nature of the study introduces the possibility of selection
bias and biased post hoc data analysis, especially when most
surgeries were performed in one institution by the senior
neurosurgeon; (2) since utilization of the intraoperative
MRI was suggested to be associated with higher extent of
resection, it could be advantageous to use this technique to
better evaluate its impact (if any) on the surgical outcomes.
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in future prospective cohort studies. However, given the
infrequency of this diagnosis, conduction of the large
prospective studies of CN may encounter significant
logistical and temporal difficulties. Therefore, creation of
prospective multi-institutional databases could become
a more practical approach. Continuous refinement of
microsurgical techniques, utilization of new technology, such
as intraoperative MRI and judicious use of multimodality
treatment may lead to further improvement in the outcomes,
reduce morbidity and mortality.[8,17,23,41,51]
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